[1] Bray F, Ferlay J, Soerjomataram I, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin 2018; 68: 394-424.
[2] Herbst RS, Heymach JV, and Lippman SM, Lung cancer, N Engl J Med 2008; 359: 1367-1380.
[3] Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med 2004; 350: 2129-2139.
[4] Pao W, and Chmielecki J, Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer, Nat Rev Cancer 2010; 10: 760-774.
[5] Ettinger DS, Wood DE, Aisner DL, et al., Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 2017; 15: 504-535.
[6] Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med 2005; 2: e73.
[7] Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med 2005; 2: e17.
[8] Engelman JA, Mukohara T, Zejnullahu K, et al., Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, J Clin Invest 2006; 116: 2695-2706.
[9] Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science 2007; 316: 1039-1043.
[10] Sequist LV, Waltman BA, Dias-Santagata D, et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med 2011; 3: 75ra26.
[11] Ornitz DM, and Itoh N, The Fibroblast Growth Factor signaling pathway, Wiley Interdiscip Rev Dev Biol 2015; 4: 215-266.
[12] Beenken A, and Mohammadi M, The FGF family: biology, pathophysiology and therapy, Nat Rev Drug Discov 2009; 8: 235-253.
[13] Wang K, Ji W, Yu Y, et al., FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer, Oncogene 2018; 37: 5340-5354.
[14] Konermann S, Brigham MD, Trevino AE, et al., Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature 2015; 517: 583-588.
[15] Vad-Nielsen J, Lin L, Bolund L, et al., Golden Gate Assembly of CRISPR gRNA expression array for simultaneously targeting multiple genes, Cell Mol Life Sci 2016; 73: 4315-4325.
[16] Weiss J, Sos ML, Seidel D, et al., Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer, Sci Transl Med 2010; 2: 62ra93.
[17] Malchers F, Dietlein F, Schottle J, et al., Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer, Cancer Discov 2014; 4: 246-257.
[18] Facchiano A, Russo K, Facchiano AM, et al., Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties, J Biol Chem 2003; 278: 8751-8760.
[19] Turner N, Pearson A, Sharpe R, et al., FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer, Cancer Res 2010; 70: 2085-2094.
[20] Matsumoto K, Arao T, Hamaguchi T, et al., FGFR2 gene amplification and clinicopathological features in gastric cancer, Br J Cancer 2012; 106: 727-732.
[21] Lu J, Zhong H, Chu T, et al., Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy, Eur Respir J 2019; 53:
[22] Lin B, Song X, Yang D, et al., Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1, Gene 2018; 654: 77-86.
[23] Ashton S, Song YH, Nolan J, et al., Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo, Sci Transl Med 2016; 8: 325ra317.
[24] Wang C, Chen J, Cao W, et al., Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways, Eur J Pharmacol 2016; 779: 1-7.
[25] Ambrogio C, Gomez-Lopez G, Falcone M, et al., Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma, Nat Med 2016; 22: 270-277.
[26] Kakiuchi-Kiyota S, Lappin PB, Heintz C, et al., Expression of proto-oncogene cFMS protein in lung, breast, and ovarian cancers, Appl Immunohistochem Mol Morphol 2014; 22: 188-199.
[27] Koizumi F, Shimoyama T, Taguchi F, et al., Establishment of a human non-small cell lung cancer cell line resistant to gefitinib, Int J Cancer 2005; 116: 36-44.
[28] Zhang N, Zeng Y, Du W, et al., The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer, Int J Oncol 2016; 49: 1360-1368.
[29] Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science 2004; 304: 1497-1500.
[30] Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med 2009; 361: 947-957.
[31] Turner N, and Grose R, Fibroblast growth factor signalling: from development to cancer, Nat Rev Cancer 2010; 10: 116-129.
[32] Knights V, and Cook SJ, De-regulated FGF receptors as therapeutic targets in cancer, Pharmacol Ther 2010; 125: 105-117.
[33] Wesche J, Haglund K, and Haugsten EM, Fibroblast growth factors and their receptors in cancer, Biochem J 2011; 437: 199-213.